A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness
Metabolic Dysfunction-Associated Steatohepatitis
Bristol-Myers Squibbprotein_peptidePhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 89/ 100
Competitive context
128 Active assets in the Metabolic Dysfunction-Associated Steatohepatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Resmetirom City University of New York | Phase 4 | BBB |
Pentoxifylline Al-Azhar University | Phase 4 | BBB |
Pioglitazone Badr University | Phase 4 | BBB |
Firsocostat Gilead Sciences | Phase 2 | BBB |
Montelukast Tanta University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative · Phase 2
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →